(NASDAQ: FDMT) 4d Molecular Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.
4d Molecular Therapeutics's earnings in 2026 is -$140,109,000.On average, 11 Wall Street analysts forecast FDMT's earnings for 2026 to be -$181,156,202, with the lowest FDMT earnings forecast at -$215,130,966, and the highest FDMT earnings forecast at -$139,370,560. On average, 10 Wall Street analysts forecast FDMT's earnings for 2027 to be -$179,522,554, with the lowest FDMT earnings forecast at -$247,650,763, and the highest FDMT earnings forecast at -$73,437,564.
In 2028, FDMT is forecast to generate -$203,082,815 in earnings, with the lowest earnings forecast at -$311,689,749 and the highest earnings forecast at -$108,816,245.